SCHEMBL24317439

SCHEMBL24317439

O=C1Nc2cccc3c(Cc4ccc(F)c(Cl)c4)ccc1c23

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.41
BRD4 O60885 2/20 0.38
POLB P06746 2/20 0.38
KDR P35968 1/20 0.38
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
TDP2 O95551 1/20 0.37
TNF P01375 1/20 0.36
KDM4E B2RXH2 7/20 0.36
ALDH1A1 P00352 7/20 0.36
HPGD P15428 5/20 0.36
CASP1 P29466 3/20 0.36
CASP7 P55210 3/20 0.36
HSD17B10 Q99714 3/20 0.36
CDK2 P24941 2/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
CREBBP Q92793 1/20 0.36
HTT P42858 1/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24317445 0.78 PDE3B (0.42) POLBKDRKDM4EALDH1A1HPGD
SCHEMBL27454006 0.76 CDK5 (0.51) PARP1BRD4POLBKDRCDK5
SCHEMBL24317641 0.75 CHEK1 (0.41) PARP1POLBKDRCDK5CDK5R1
SCHEMBL24317629 0.75 MAOB (0.43) POLBKDRCDK5CDK5R1KDM4E
SCHEMBL29774602 0.74 ALDH1A1 (0.48) PARP1POLBCDK5CDK5R1KDM4E
SCHEMBL22532771 0.74 ALDH1A1 (0.48) PARP1POLBCDK5CDK5R1KDM4E
SCHEMBL22532983 0.73 DRD4 (0.40) PARP1POLBKDM4EALDH1A1GLA
SCHEMBL7300968 0.73 CDK5 (0.50) POLBCDK5CDK5R1KDM4EALDH1A1
SCHEMBL24317881 0.73 MAPT (0.53) POLBKDRCDK5CDK5R1KDM4E
SCHEMBL22532759 0.73 CDK5 (0.47) PARP1BRD4POLBCDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 PARP1 328/4885BRD4 360/4885POLB 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.